Company & Sponsor Intelligence

Jazz Pharmaceuticals

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials21

Recruiting4

Completed13

Countries3

Therapeutic footprint

anxietyepilepsymovement_disordersmultiple_sclerosisother_neurologypain_neuropathyptsdschizophreniasleep_disorders

Indexed studies

NCT02091206A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
epilepsy · United StatesPHASE2

NCT03101241A Phase 2 RCT Study of CX-8998 for Essential Tremor
movement_disorders · United StatesPHASE2

NCT04203498Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
multiple_sclerosis · United StatesPHASE3

NCT02224703GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
epilepsy · United StatesPHASE3

NCT07723976A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
epilepsy · PHASE3

NCT00371137A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia
pain_neuropathy · United StatesPHASE3

NCT02565108A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
epilepsy · SpainPHASE2

NCT05178316A Study of JZP150 in Adults With Posttraumatic Stress Disorder
ptsd · United StatesPHASE2

NCT03406702CX-8998 for Absence Seizures
epilepsy · United StatesPHASE2

NCT05864846A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
epilepsy · United StatesPHASE4

NCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
epilepsy · ItalyACTIVE_NOT_RECRUITING

NCT02954887Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
other_neurology · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →